Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Mapracorat, a selective glucocorticoid receptor agonist, upregulates RelB, an anti-inflammatory nuclear factor-kappaB protein, in human ocular cells.

Authors: Spinelli, Sherry L; Xi, Xia; McMillan, David H; Woeller, Collynn F; Richardson, Mary E; Cavet, Megan E; Zhang, Jin-Zhong; Feldon, Steven E; Phipps, Richard P

Published In Exp Eye Res, (2014 Oct)

Abstract: Selective glucocorticoid receptor agonists (SEGRAs) are a new class of compounds under clinical evaluation for treatment of ocular inflammation. Widely prescribed therapeutics, such as glucocorticoids, are effective at reducing ocular inflammation, but their long term use predisposes to undesirable side effects. The purpose of this study was to investigate a novel SEGRA, mapracorat (BOL-303242-X), and the differences in mapracorat's mechanism of action compared with traditional steroids (i.e. dexamethasone). Keratocytes from three different humans were cultured and treated with mapracorat or dexamethasone, with and without a strong provoking agent, interleukin (IL)-1β. The effects of mapracorat compared to dexamethasone were determined by measuring protein levels (Western blotting) and DNA binding (ELISA) for two nuclear factor-kappaB (NF-κB) family members, RelA and RelB. Cytokine production (i.e. IL-6, IL-8, prostaglandin E2 (PGE2)) was characterized by immunoassay. Our findings reveal mechanistic differences between mapracorat and traditional steroid therapies. Mapracorat showed partial attenuation of the classical NF-κB pathway, consistent with traditional steroids. However, mapracorat uniquely potentiated a novel anti-inflammatory mechanism through rapid upregulation of RelB, an anti-inflammatory member of the NF-κB alternative pathway. Mapracorat potently inhibits ocular inflammation in vitro and is a promising new treatment for ocular inflammatory disease. Mapracorat acts, in part, by a novel mechanism via upregulation of RelB in the NF-κB alternative pathway.

PubMed ID: 25245083 Exiting the NIEHS site

MeSH Terms: Anti-Inflammatory Agents/pharmacology*; Benzofurans/pharmacology*; Blotting, Western; Cells, Cultured; Corneal Keratocytes/drug effects*; Corneal Keratocytes/metabolism; Cytokines/metabolism; Dexamethasone/pharmacology; Enzyme-Linked Immunosorbent Assay; Glucocorticoids/pharmacology; Humans; NF-kappa B/metabolism*; Pentanols/pharmacology*; Quinolines/pharmacology*; Receptors, Glucocorticoid/agonists*; Transcription Factor RelA/metabolism; Transcription Factor RelB/metabolism*; Up-Regulation

Back
to Top